Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Tom noted post-surgery ctDNA positivity fell to 5% on EV+Pembro versus 15% on chemotherapy, and the chemo arm also declined. He suspects surgery accounts for only part of the drop, with delayed immune clearance from EV+Pembro contributing; the durability of response evolves over months. So the surgical effect is not the whole story.

Related Insights

Not all ctDNA clearance is equal. Data from KEYNOTE-361 shows chemotherapy clears ctDNA more frequently (40%) but with poor correlation to outcomes. In contrast, immunotherapy clears ctDNA less often (11%), but those patients who do clear it experience brilliant, more durable outcomes, suggesting a different biological mechanism of response.

While trials like IMvigor011 show ctDNA can guide adjuvant immunotherapy after surgery, this data may not apply to the new standard of care. With neoadjuvant EV/pembrolizumab becoming prevalent, the prognostic and predictive value of post-operative ctDNA is now unknown, requiring new prospective studies.

Tom argued pCR reflects local drug activity in the bladder and matters less when everyone undergoes cystectomy, while ctDNA reflects clearance of micrometastases. Their imperfect alignment is expected because the tests measure different processes and have different sensitivity and specificity. Neither is a complete proxy for the other.

The type of treatment inducing ctDNA clearance matters. Clearance from immunotherapy appears to be more permanent and strongly prognostic than clearance from chemotherapy, which can be transient. This suggests immunotherapy may achieve a more profound and lasting elimination of cancer cells versus cytotoxic agents.

John Chatzko reported that 82% of baseline ctDNA-positive patients cleared ctDNA before surgery on EV+Pembro versus 67% on gem/cis. Among those clearers, two-year EFS was 81% versus 63%, suggesting EV+Pembro drives a deeper biologic response. That gap implies the quality, not just frequency, of clearance differs by regimen.

Unlike immunotherapy, where ctDNA clearance strongly predicts good outcomes, chemotherapy can cause a temporary decrease in ctDNA that doesn't correlate with long-term survival. This "smudging" effect complicates ctDNA interpretation for patients receiving chemo-immunotherapy combinations.

In neoadjuvant therapy, a patient's long-term outcome is better predicted by stopping tumor DNA shedding (ctDNA clearance) than by achieving pathologic complete response (pCR), the traditional gold standard. This redefines what constitutes a successful treatment response before surgery.

Tom said no pre-surgery ctDNA-positive patient achieved pCR in EV304 or Niagara. Among ctDNA-negative patients, pCR was 75% with EV+Pembro but roughly 50-50 with chemotherapy. That makes bladder-sparing risky while ctDNA remains positive; the test is not a green light for less local therapy.

Tom said patients who remain ctDNA-positive after surgery, roughly 18 weeks out, have a median PFS of only about four months and do very poorly regardless of prior therapy. John Chatzko called this an unmet need and pointed to an upcoming adjuvant DATO-DXD trial as a possible option.

Tom noted 24-month EFS was 94% in EV+Pembro patients who were ctDNA-negative at baseline and stayed negative, but John Chatzko cautioned that about a quarter of pre-surgery ctDNA-negative EV+Pembro patients still lacked pCR. They favored randomized de-escalation trials over routine treatment reduction; the high survival is real, but causal attribution is not.